Turalio oral therapy?

Turalio is the brand name for pexidartinib, an oral targeted therapy.

- What it’s for: In adults, Turalio is approved for tenosynovial giant cell tumor (TGCT, also called pigmented villonodular synovitis) when the disease is associated with severe morbidity or when surgery isn’t feasible or would cause unacceptable loss of function.
- How it works: It inhibits CSF-1 receptor (CSF-1R) signaling, which helps reduce the tumor’s macrophage-driven activity.
- How it’s taken: Usually 800 mg per day (400 mg twice daily) to start, taken with or without food. The dose can be reduced if side effects occur or if drug interactions require it. The maximum daily dose is generally 1200 mg/day (e.g., three 400 mg doses). Your prescriber will tailor this based on tolerance and interactions.
- Important safety and monitoring:
- There is a risk of serious liver injury. Because of this, Turalio is given under a REMS program with strict liver-function monitoring.
- Baseline liver tests and ongoing monitoring are required (more frequent tests early in treatment).
- Common side effects include fatigue, hair color changes, nausea, diarrhea, dizziness, and edema. There can be more serious adverse effects during treatment.
- Avoid strong CYP3A4 inhibitors or inducers unless your clinician adjusts the dose.
- It’s not for use during pregnancy; contraception is advised.
- Considerations: Because of the REMS and liver-monitoring requirements, access is through specialized programs and specialists.

If you’re considering Turalio for TGCT or are discussing it with a clinician, I can provide more details on dosing specifics, monitoring schedules, potential drug interactions, or how the REMS program works. What would you like to know more about?